ALIDYA

ALIDYA is characterised by:
- Combination of Polyamino Acid Gel, D-(+)Glucopyranose ?, 1-4 Glucosidic, Sodium Ethylenediaminetetraacetic acid, Amino Acid Buffer System With Bicarbonate-Sodium Corrector, Osmolarity Regulator.
- Disposable bottles.
- Sterile content.
- Liquid formulation for injections.

- MARLLOR BIOMEDICAL
- NAME: ALIDYA
- COMPOSITION: Polyamino Acid Gel, D-(+)Glucopyranose ?, 1-4 Glucosidic, Sodium Ethylenediaminetetraacetic acid, Amino Acid Buffer System With Bicarbonate-Sodium Corrector, Osmolarity Regulator.
- PRESENTATION: 5 vials x 340 mg powder and 5 vials x 10 ml solvent.
- INDICATIONS: Reduction of localised adiposity and treatment of cellulite.
- INJECTION DEPTH: Injections for the external subacute part of the skin (mesotherapy).
- DURATION: The ALIDYA treatment requires on average a minimum of 7 applications in the specific area to be treated up to a maximum of 12 treatments. To be applied on a weekly basis, with 1-2 ampoules each session, depending on the extent of the area to be treated. Monthly maintenance treatments are generally recommended to improve the duration of the results.
- USE: Strict medical use.

- Bottles: 5 x 340 mg powder.
- Vials: 5 x 10ml solvent.
- Each box contains 5 ampoules x 340 mg powder and 5 ampoules x 10 ml solvent of ALIDYA disposable and sterile.

Prevention and treatment of gynoid lipodystrophy (cellulite). Area of application: body (legs, buttocks, thighs, upper arms).

- Polyamino acid gel.
- D-(+)Glucopyranose ?.
- 1-4 Glucosidic.
- Sodium Ethylenediaminetetraacetic acid.
- Amino acid buffer system with bicarbonate-sodium corrector.
- Osmolarity regulator.

- Professional use only: the product should only be used by qualified medical personnel with experience in mesotherapy techniques or lipolytic treatments.
- Preliminary medical assessment: before administration, a comprehensive patient history must be taken to identify any contraindications or risk factors.
- Injection technique: Correct injection technique is essential to avoid complications such as lumps, bruising, infection or inflammation. The use of sterile needles and syringes, appropriate for the area of application, is recommended.
- Do not inject in sensitive or inappropriate areas: avoid use in unsuitable areas, such as near large blood vessels, nerves or inflamed tissue.
- Hygiene and sterility: Ensure aseptic conditions throughout treatment to prevent infection. Thoroughly disinfect the area to be treated before injection.
- Post-treatment monitoring: observe the patient over the next few hours for any immediate adverse reactions. Temporary slight swelling or redness in the treated area is normal.
- Interval between sessions: respect the recommended intervals between sessions (normally one week), avoiding treatments that are too close together.
- Avoid exposure to heat sources or intense physical activity in the 24-48 hours following treatment.
- Informing the patient: the patient must be clearly informed about the realistic goals of the treatment, potential side effects and post-procedure care.

The use of ALIDYA is contraindicated in the following cases:
- Pregnancy and lactation: treatment is not recommended during pregnancy or lactation, as there are insufficient data available on the safety of the product under these conditions.
- Allergy to product components: contraindicated in the event of known hypersensitivity or allergy to one or more ingredients in the formulation.
- Infection or inflammation in the treatment area: do not administer in skin areas affected by infection, active inflammation or injury.
- Autoimmune disorders or serious systemic diseases: conditions such as lupus, scleroderma or other autoimmune diseases may increase the risk of adverse reactions.
- Clotting disorders or use of anticoagulants: administration may increase the risk of bleeding, bruising or bruising.
- Under 18 years of age: the safety and efficacy of the product have not been established in minors.
- Presence of hypertrophic or keloid scars: not recommended for individuals predisposed to abnormal scar formation.
- Recent aesthetic treatments in the same area: use in areas already recently treated with fillers, medical devices or other lipolytic agents is not recommended, to avoid possible interactions or complications.

ALIDYA is a lipolytic to solubilise and remove toxic extracellular elements secondary to damage of the vascular microcirculation, alkalinise the extracellular matrix, improve tissue oxygenation, provide biological components for restructuring the extracellular matrix, and normalise the physiological function of adipose tissue.